Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)
After wrestling with the Sandoz problem for several years, Vas Narasimhan settles on a spinout
Novartis CEO Vas Narasimhan has finally figured out how he can get Sandoz off his list of major headaches. He’s going to spin the generics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
